Population pharmacokinetic modeling and simulation for nirmatrelvir exposure assessment in Chinese older patients with COVID-19 infection
Author:
Publisher
Elsevier BV
Subject
Pharmaceutical Science
Reference20 articles.
1. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis;Amani;J. Med. Virol.,2023
2. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models;Bergstrand;AAPS J.,2011
3. Aging in COVID-19: vulnerability, immunity and intervention;Chen;Ageing Res. Rev.,2021
4. Assessment of aging-related function variations of P-gp transporter in old-elderly Chinese CHF patients based on modeling and simulation;Cui;Clin. Pharmacokinet.,2022
5. FDA. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19, U.S. Food and Drug Administration, 2021.
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future;Advanced Drug Delivery Reviews;2024-08
2. Population pharmacokinetics of nirmatrelvir in Chinese patients with COVID-19: Therapeutic drug monitoring and dosing regimen selection in clinical practice;International Journal of Antimicrobial Agents;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3